Median Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Median Technologies wird ein Gewinn- und Umsatzwachstum von 9.1% bzw. 21.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 14% pro Jahr wachsen soll.

Wichtige Informationen

9.1%

Wachstumsrate der Gewinne

14.0%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	21.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	27 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:4ZG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	37	-17	-17	-14	2
12/31/2025	44	-21	-18	-20	4
12/31/2024	24	-25	-22	-23	2
12/31/2023	23	-23	-22	-20	N/A
9/30/2023	23	-22	-20	-19	N/A
6/30/2023	23	-21	-19	-18	N/A
3/31/2023	23	-21	-18	-17	N/A
12/31/2022	24	-20	-17	-16	N/A
9/30/2022	24	-19	-16	-15	N/A
6/30/2022	23	-19	-15	-14	N/A
3/31/2022	22	-19	-13	-12	N/A
12/31/2021	21	-19	-11	-10	N/A
9/30/2021	19	-18	-10	-10	N/A
6/30/2021	18	-18	-10	-9	N/A
3/31/2021	16	-15	-8	-7	N/A
12/31/2020	14	-13	-6	-5	N/A
9/30/2020	12	-11	-4	-4	N/A
6/30/2020	11	-8	-3	-2	N/A
3/31/2020	10	-8	-4	-3	N/A
12/31/2019	9	-8	-5	-4	N/A
9/30/2019	8	-9	-8	-7	N/A
6/30/2019	7	-11	-11	-10	N/A
3/31/2019	7	-13	-13	-13	N/A
12/31/2018	6	-15	-16	-16	N/A
9/30/2018	7	-16	-17	-17	N/A
6/30/2018	7	-17	-18	-18	N/A
3/31/2018	7	-17	-16	-16	N/A
12/31/2017	8	-17	-14	-14	N/A
9/30/2017	8	-16	N/A	-12	N/A
6/30/2017	7	-14	N/A	-10	N/A
3/31/2017	7	-12	N/A	-9	N/A
12/31/2016	6	-9	N/A	-8	N/A
9/30/2016	6	-8	N/A	-6	N/A
6/30/2016	5	-7	N/A	-5	N/A
3/31/2016	5	-6	N/A	-4	N/A
12/31/2015	4	-6	N/A	-4	N/A
9/30/2015	3	-5	N/A	-4	N/A
6/30/2015	2	-5	N/A	-5	N/A
3/31/2015	2	-5	N/A	-4	N/A
12/31/2014	2	-4	N/A	-3	N/A
9/30/2014	1	-4	N/A	N/A	N/A
6/30/2014	1	-4	N/A	N/A	N/A
3/31/2014	1	-4	N/A	N/A	N/A
12/31/2013	1	-4	N/A	-4	N/A
9/30/2013	1	-4	N/A	N/A	N/A
6/30/2013	1	-4	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4ZG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 4ZG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 4ZG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 4ZGDie Einnahmen des Unternehmens (27.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (5.1% pro Jahr).

Hohe Wachstumseinnahmen: 4ZGDie Einnahmen des Unternehmens (27.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 4ZG in 3 Jahren voraussichtlich hoch sein wird

Median Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2025

Recent updates

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: €1.25 loss per share (vs €1.28 loss in FY 2022)

New major risk - Share price stability

New minor risk - Share price stability

Median Technologies SA to Report Fiscal Year 2023 Results on Apr 25, 2024

Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress

Median Technologies Appoints Ben Mcdonald to Its Board of Directors

Median Technologies SA, Annual General Meeting, Oct 10, 2023

Median Technologies SA to Report First Half, 2023 Results on Oct 19, 2023

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: €1.28 loss per share (vs €1.25 loss in FY 2021)

Forecast to breakeven in 2025

Median Technologies SA to Report Fiscal Year 2022 Results on Apr 20, 2023

No independent directors

First half 2022 earnings released: €0.57 loss per share (vs €0.65 loss in 1H 2021)

Median Technologies Announces Formation of Clinical Advisory Board for Ibiopsy Lung Cancer Screening

Median Technologies SA to Report Q3, 2022 Results on Oct 20, 2022

Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials

Median Technologies SA, Annual General Meeting, Jun 14, 2022

No independent directors

Full year 2021 earnings released: €1.25 loss per share (vs €1.06 loss in FY 2020)

Median Technologies SA Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median Technologies Announces New Outstanding Performance for Its iBiopsy® Lung Cancer Screening CADx With a Focus on Stage 1 Lung Cancer Characterization

First half 2021 earnings released: €0.65 loss per share (vs €0.39 loss in 1H 2020)

Median Technologies SA announced that it has received €28.1 million in funding

Full year 2020 earnings released: €1.05 loss per share (vs €0.66 loss in FY 2019)

Median Technologies Appoints Thomas Bonnefont as Chief Operating and Commercial Officer

Median Technologies Sa Unveils New iBiopsy® Clinical Development Plan on Lung Cancer Screening

Median Technologies Inks Major Research Collaboration Agreement With the University of California San Diego

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken